menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

A Review of Biosimilars in Retina

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Comments
  • Overview

    As we enter the era of biosimilars in retina, Clinical Minute: Retina host Ramin Tadayoni, MD, PhD, invites Prof. Frank Holz to update viewers on the state of biosimilars in retina. Together, they will discuss what biosimilars are, how they are approved, whether they might offer cost savings to healthcare systems, and which markets might be best suited for rapid biosimilar adoption.

    View video on Eyetube here.

Facebook Comments

Recommended
Details
Comments
  • Overview

    As we enter the era of biosimilars in retina, Clinical Minute: Retina host Ramin Tadayoni, MD, PhD, invites Prof. Frank Holz to update viewers on the state of biosimilars in retina. Together, they will discuss what biosimilars are, how they are approved, whether they might offer cost savings to healthcare systems, and which markets might be best suited for rapid biosimilar adoption.

    View video on Eyetube here.

Facebook Comments

Schedule15 Apr 2024